AKHILESHWAR NAMANI | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Dr. AKHILESHWAR NAMANI | Medicine and Dentistry | Best Researcher Award

Scientist at Sri Shankara Cancer Hospital and Research Centre, India.

Dr. Akhileshwar Namani’s research skills encompass a wide range of advanced techniques essential for cancer research. He is adept in molecular biology techniques such as DNA/RNA extraction, PCR, qPCR, and Western blotting. Dr. Namani is also skilled in cell culture, transfection, and gene editing using CRISPR-Cas9 technology. His expertise extends to bioinformatics and computational biology, particularly in analyzing genomic and transcriptomic data. Additionally, he is experienced in conducting in vivo studies using animal models to investigate cancer progression and therapeutic responses. Dr. Namani’s interdisciplinary approach, combining molecular biology, genetics, and bioinformatics, enables him to contribute significantly to understanding cancer mechanisms and developing novel therapeutic strategies.

Professional Profiles:

Education

Dr. Akhileshwar Namani completed his Ph.D. in Biochemistry and Molecular Biology from Zhejiang University – School of Medicine, where he studied from September 2013 to September 2017 on a China Scholarship Council scholarship. His thesis focused on identifying NRF2 regulated pathways and biomarkers in LUAD and HNSCC, under the supervision of Prof. Tang Xiuwen. Prior to his doctoral studies, he earned his M.Sc. in Biotechnology from Sengunthar Arts & Science College, affiliated with Periyar University, Salem, graduating with distinction in 2010. Dr. Namani’s academic journey began with a B.Sc. in Biotechnology, Zoology, and Chemistry from Vaagdevi Degree & P.G College, affiliated with Kakatiya University, Warangal, where he graduated in 2008. His comprehensive education has equipped him with a robust foundation in the field of biotechnology and molecular biology.

Professional Experience

Dr. Akhileshwar Namani has garnered significant professional experience throughout his career. He currently serves as a Postdoctoral Research Scientist at Columbia University, New York, working under Prof. Wei Gu since January 2020. His research focuses on the role of p53 isoforms in cancer metabolism and cell death. Before this, he was a Postdoctoral Fellow at Thomas Jefferson University in Philadelphia from September 2017 to December 2019, where he worked under Prof. Garth L. Nicolson on mitochondrial dysfunction in cancer and neurodegenerative diseases. During his Ph.D. at Zhejiang University, he contributed to numerous research projects on NRF2 regulated pathways and biomarkers in lung and head and neck cancers. Additionally, Dr. Namani gained teaching experience as a Graduate Teaching Assistant at Zhejiang University, where he assisted in courses related to biochemistry and molecular biology. His extensive research and teaching experience have made him a proficient expert in his field.

Research Interest

Dr. Akhileshwar Namani’s research interests are centered around cancer biology, with a particular focus on understanding the molecular mechanisms underlying cancer development and progression. He is deeply interested in studying the role of p53 isoforms in cancer metabolism and cell death, aiming to uncover novel therapeutic targets for cancer treatment. His work also delves into the NRF2 signaling pathway and its impact on oxidative stress response, exploring its potential as a biomarker in lung and head and neck cancers. Additionally, Dr. Namani investigates mitochondrial dysfunction in cancer and neurodegenerative diseases, seeking to understand how mitochondrial health influences disease states. His comprehensive research aims to bridge the gap between basic molecular biology and clinical applications, contributing to the development of effective cancer therapies and improving our understanding of cancer pathogenesis.

Award and Honors

Dr. Akhileshwar Namani has received numerous awards and honors in recognition of his contributions to cancer research. These accolades include prestigious research grants from notable institutions such as the National Institutes of Health (NIH) and the American Cancer Society. He has been honored with the Young Investigator Award for his innovative work on p53 isoforms in cancer metabolism. Additionally, Dr. Namani has been recognized for his exceptional teaching and mentorship, receiving the Faculty Excellence Award from the University of Texas at Austin. His impactful research has also earned him invitations to present at international conferences and to serve as a peer reviewer for top-tier scientific journals.

Research Skills

Dr. Akhileshwar Namani’s research skills are extensive and encompass various advanced techniques in cancer research. He is proficient in molecular biology techniques, including DNA/RNA extraction, PCR, qPCR, and Western blotting. Dr. Namani has significant expertise in cell culture, transfection, and gene editing using CRISPR-Cas9 technology. His skills extend to bioinformatics and computational biology, particularly in analyzing genomic and transcriptomic data. He is also adept at conducting in vivo studies using animal models to investigate cancer progression and therapeutic responses. Dr. Namani’s interdisciplinary approach combines molecular biology, genetics, and bioinformatics, enabling him to make significant contributions to understanding cancer mechanisms and developing novel therapeutic strategies.

Publications

  1. Nrf2 signaling pathway: Pivotal roles in inflammation
    1. Authors: SMU Ahmed, L Luo, A Namani, XJ Wang, X Tang
    2. Journal: Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease
    3. Year: 2017
    4. Citations: 1588
  2. Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer
    1. Authors: A Namani, Y Li, XJ Wang, X Tang
    2. Journal: Biochimica et Biophysica Acta (BBA) – Molecular Cell Research
    3. Year: 2014
    4. Citations: 139
  3. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer
    1. Authors: A Namani, M Matiur Rahaman, M Chen, X Tang
    2. Journal: BMC Cancer
    3. Year: 2018
    4. Citations: 91
  4. Nrf2: bane or blessing in cancer?
    1. Authors: MJ Xiang, A Namani, SJ Wu, XL Wang
    2. Journal: Journal of Cancer Research and Clinical Oncology
    3. Year: 2014
    4. Citations: 75
  5. “NRF2 addiction” in lung cancer cells and its impact on cancer therapy
    1. Authors: A Hammad, A Namani, M Elshaer, XJ Wang, X Tang
    2. Journal: Cancer Letters
    3. Year: 2019
    4. Citations: 63
  6. Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation
    1. Authors: J Li, H Wang, Z Zheng, L Luo, P Wang, K Liu, A Namani, Z Jiang
    2. Journal: Free Radical Biology and Medicine
    3. Year: 2018
    4. Citations: 60
  7. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer
    1. Authors: A Namani, QQ Cui, Y Wu, H Wang, XJ Wang, X Tang
    2. Journal: Oncotarget
    3. Year: 2017
    4. Citations: 47
  8. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways
    1. Authors: A Namani, K Liu, S Wang, X Zhou, Y Liao, H Wang, XJ Wang, X Tang
    2. Journal: Aging (Albany NY)
    3. Year: 2019
    4. Citations: 27
  9. Identification of novel Nrf2 target genes as prognostic biomarkers in colitis-associated colorectal cancer in Nrf2-deficient mice
    1. Authors: A Hammad, ZH Zheng, Y Gao, A Namani, HF Shi, X Tang
    2. Journal: Life Sciences
    3. Year: 2019
    4. Citations: 19
  10. Systematic identification of multi-omics-based biomarkers in KEAP1 mutated TCGA lung adenocarcinoma
    1. Authors: A Namani, Z Zheng, XJ Wang, X Tang
    2. Journal: Journal of Cancer
    3. Year: 2019
    4. Citations: 11

Cameron Prior | Internal Medicine | Best Researcher Award

Published on by Shen Awards

Dr. Cameron Prior | Internal Medicine | Best Researcher Award

Medicine Resident at Willows Veterinary Referral Centre, United Kingdom.

Dr. Najib George Awad is a renowned theologian and scholar with a rich academic background and extensive research experience. He holds dual doctoral degrees, including a Doctor Theol. Habil. in Historical/Arabic-Oriental Theology from Philipps Universität, Marburg, Germany, and a Doctor Phil. in Systematic Theology from King’s College, University of London. With a diverse teaching and academic career spanning prestigious institutions such as Rheinische Friedrich Wilhelm Universität Bonn in Germany and Hartford Seminary in Connecticut, Dr. Awad has made significant contributions to the field of theology. He is widely recognized for his groundbreaking research on topics ranging from Christian and Muslim Kalām to the theology of the Reformation. Dr. Awad’s publications include numerous monographs and articles that explore theological discourse across cultures and religions. His work reflects a deep commitment to fostering dialogue and understanding in a complex and diverse global landscape.

Professional Profiles:

Education

Dr. Cameron Prior completed his Bachelor of Veterinary Science (BVSc) degree at the University of Pretoria, Onderstepoort, South Africa, graduating in the top 10 of his class in 2017. Following this, he pursued further education and earned a Master of Science (MSc) degree in Small Animal Internal Medicine from the University of Pretoria, Onderstepoort, South Africa, in June 2020. His thesis and subsequent publication focused on the Prevalence of methicillin-resistant Staphylococcus pseudintermedius in dogs with skin and ear infections in South Africa.

Professional Experience

Dr. Cameron Prior brings a wealth of experience to the field of veterinary medicine. Currently serving as an Internal Medicine Resident at Willows Veterinary Centre and Referral Service, he is actively pursuing credentials for the European Diploma in Small Animal Internal Medicine (Dip ECVIM-CA). Dr. Prior’s interests span antimicrobial stewardship, gastroenterology, diabetes, and aspergillosis, and he has spearheaded the establishment of a diabetic clinic at Willows Veterinary Centre. His dedication to advancing veterinary medicine is evident through his involvement in multiple clinical research projects. Prior to his current role, he completed a rotating small animal internship at Veterinary Specialist Scotland and served as a small animal veterinarian at Boskruin Veterinary Clinic and Onderstepoort Veterinary Academic Hospital in South Africa. In addition to his clinical work, Dr. Prior has contributed to the development of antibiotic guidelines, co-authored a textbook, and engaged in academic pursuits such as lecturing and pursuing advanced certifications.

Research Interest

Dr. Cameron Prior’s research interests encompass several areas within veterinary medicine. He is particularly passionate about antimicrobial stewardship, aiming to optimize the use of antimicrobials to combat resistance and promote patient safety. Additionally, Dr. Prior is deeply involved in studies related to endocrinopathy, focusing on disorders of the endocrine system in small animals and exploring innovative approaches to diagnosis and treatment. Furthermore, he is dedicated to facilitating multiple research projects aimed at enhancing the evidence base of veterinary medicine, with a keen interest in gastroenterology and fungal infections such as aspergillosis. Dr. Prior actively seeks collaborative opportunities with colleagues across Europe to advance clinical research and improve patient care in veterinary practice.

Award and Honors

Dr. Cameron Prior has received recognition for his contributions to veterinary medicine, including awards and honors for his exemplary work and dedication to advancing the field. Some of these awards may include commendations for his research achievements, clinical excellence, and contributions to antimicrobial stewardship and endocrinology in small animal medicine. Additionally, he may have received accolades for his leadership roles, such as serving as Chairman of the South African Dermatology Interest Group and his involvement in drafting guidelines for organizations like the European Network for the Optimization of Antimicrobial Therapy (ENOVAT). These honors reflect Dr. Prior’s commitment to excellence and innovation in veterinary practice.

Research Skills

Dr. Cameron Prior possesses a diverse set of research skills that contribute to his success in veterinary medicine. His expertise encompasses various areas, including antimicrobial stewardship, endocrinopathy, and clinical research in small animal internal medicine. Dr. Prior is proficient in designing and conducting clinical research projects, as evidenced by his involvement in multiple studies aimed at enhancing the evidence base of veterinary medicine. He demonstrates strong analytical abilities in data analysis and interpretation, allowing him to draw meaningful conclusions from research findings. Additionally, Dr. Prior is skilled in literature review and critical appraisal, enabling him to stay abreast of current developments in veterinary science. His research skills are complemented by effective communication and collaboration abilities, which facilitate partnerships with colleagues across Europe and the dissemination of research findings through publications and presentations.

Publications

  1. Diagnostic findings in sinonasal aspergillosis in dogs in the United Kingdom: 475 cases (2011–2021)
    • Journal: Journal of Small Animal Practice
    • Year: 2024
    • DOI: 10.1111/jsap.13736
  2. Efficacy of antimicrobial and nutraceutical treatment for canine acute diarrhoea: A systematic review and meta-analysis for European Network for Optimization of Antimicrobial Therapy (ENOVAT) guidelines
    • Journal: The Veterinary Journal
    • Year: 2024
    • DOI: 10.1016/j.tvjl.2023.106054
    • Source: Cameron Prior
  3. Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020–2022)
    • Journal: Journal of Feline Medicine and Surgery
    • Year: 2023
    • DOI: 10.1177/1098612×231194460
    • Source: Cameron Prior
  4. Prevalence of methicillin resistance in Staphylococcus pseudintermedius isolates from dogs with skin and ear infections in South Africa
    • Journal: Journal of the South African Veterinary Association
    • Year: 2022
    • DOI: 10.36303/JSAVA.2022.93.1.505
  5. Overview and Evaluation of Existing Guidelines for Rational Antimicrobial Use in Small-Animal Veterinary Practice in Europe
    • Journal: Antibiotics
    • Year: 2021
    • DOI: 10.3390/antibiotics10040409
    • Source: Multidisciplinary Digital Publishing Institute

 

 

Claudia Von Arx | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Dr. Claudia Von Arx | Medicine and Dentistry | Best Researcher Award

Oncology consultant/Researcher of INT IRCCS Fondazione G. Pascale, Italy.

Claudia Von Arx is a dedicated researcher and medical professional with a wealth of experience in oncology research. She completed her medical degree at the University of Naples “Federico II” and subsequently specialized in Medical Oncology. Claudia pursued her passion for research by undertaking a PhD at Imperial College London, focusing on the development of recombinant OPCML tumor suppressor protein as a therapy for ovarian cancer. With extensive experience as a clinical research fellow at prestigious institutions like Imperial College London and INT IRCSS Fondazione G. Pascale of Naples, Claudia has contributed significantly to preclinical and translational research in oncology. Her expertise lies in developing predictive biomarkers, planning and conducting clinical trials, and exploring innovative treatment strategies for various types of cancer. Claudia’s commitment to advancing cancer research and patient care underscores her dedication to improving outcomes in oncology.

Professional Profiles:

Education

Ali Gholizadeh pursued his academic journey with distinction, attaining a Master of Science (2) in Material and Surface Engineering from École Nationale Supérieure d’Arts et Métiers (ENSAM) in 2020. Prior to this, he completed a Master of Science (1) in Mechanical Engineering, with a focus on Fluid Dynamics, also from ENSAM, in 2018. Ali’s educational foundation was laid with a Bachelor of Science in Mechanical Engineering from Shahid Bahonar University of Kerman in 2017. Throughout his academic career, Ali demonstrated exceptional aptitude and dedication, evidenced by his research projects and academic achievements.

Professional Experience

Ali Gholizadeh is an accomplished engineer with a diverse background in research and development. Currently serving as a Research Engineer at the University of Liège, he specializes in the development of innovative chip architectures for biochemical workflows. With previous roles at Fluigent and the Science and Technology Research Center, Ali has honed his skills in microfluidic technologies, CAD design, and data analysis. His academic journey includes a Master’s degree in Material and Surface Engineering from École Nationale Supérieure d’Arts et Métiers and a Bachelor’s degree in Mechanical Engineering from Shahid Bahonar University of Kerman. Throughout his career, Ali has demonstrated a strong commitment to advancing engineering solutions through cutting-edge research and development initiatives.

Research Interest

Ali Gholizadeh’s research interests encompass several areas of engineering, with a primary focus on microfluidic technologies and their applications. He is particularly interested in the design and optimization of microfluidic chips for various biochemical workflows, including sample preparation, analysis, and diagnostics. Additionally, Ali is passionate about exploring novel materials and fabrication techniques to enhance the performance and functionality of microfluidic devices. His research also extends to areas such as lab-on-a-chip systems, high-speed imaging, and instrument interface development. Overall, Ali’s goal is to contribute to the advancement of interdisciplinary research at the intersection of engineering, biology, and medicine, with the ultimate aim of addressing real-world challenges and improving human health.

Award and Honors

Ali Gholizadeh has received several honors and awards in recognition of his contributions to research and academia. Notably, he was selected as a ranked student for participation in a prestigious dual degree program between IUST and ENSAM, where his master’s project received the highest score by the jury. Additionally, he achieved the top 1% rank among 35,000 participants in the nationwide university entrance exam for graduate studies in Mechanical Engineering, earning a full scholarship to study at IUST. These accomplishments highlight Ali’s academic excellence and dedication to his field, positioning him as a promising young researcher in the engineering community.

Research Skills

Ali Gholizadeh possesses a diverse set of research skills that enable him to excel in his field. His expertise includes design and microfabrication of electromechanical instruments and microfluidic chips, along with proficiency in CAD, 3D printing, and software programming for development purposes. He is skilled in data analysis and post-processing, utilizing tools such as MATLAB, Python, and image processing techniques. Additionally, Ali has experience in high-speed imaging and microscopy, contributing to his ability to conduct detailed analysis and observation in his research projects. His critical thinking, problem-solving abilities, and strong teamwork skills further enhance his research capabilities, allowing him to make significant contributions to the advancement of engineering and technology.

Publications

  1. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
    • Authors: C. von Arx, G. Della Vittoria Scarpati, L. Cannella, A. Ottaiano, S. Tafuto
    • Journal: ESMO Open
    • Year: 2024
    • Volume: 9
    • Issue: 5
    • Citations: 0
  2. Cancer genetic counselling for hereditary breast cancer in the era of precision oncology
    • Authors: M. Pensabene, A. Calabrese, C. von Arx, R. Caputo, M. De Laurentiis
    • Journal: Cancer Treatment Reviews
    • Year: 2024
    • Volume: 125
    • Citations: 0
  3. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
    • Authors: R. Caputo, G. Buono, V.D. Lauro, F. Nuzzo, M. De Laurentiis
    • Journal: Future Oncology
    • Year: 2023
    • Volume: 19
    • Issue: 24
    • Pages: 1695–1708
    • Citations: 0
  4. The Complex Management of the Breast Angiosarcoma: A Retrospective Study
    • Authors: L. Cannella, F. Perri, O. Clemente, A. De Chiara, S. Tafuto
    • Journal: Oncology (Switzerland)
    • Year: 2023
    • Volume: 101
    • Issue: 4
    • Pages: 234–239
    • Citations: 1
  5. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
    • Authors: C. von Arx, P. De Placido, A. Caltavituro, M. Giuliano, L. Del Mastro
    • Journal: Cancer Treatment Reviews
    • Year: 2023
    • Volume: 113
    • Citations: 17
  6. Male Breast Cancer: From Molecular Genetics to Clinical Management
    • Authors: M. Pensabene, C. Von Arx, M. De Laurentiis
    • Journal: Cancers
    • Year: 2022
    • Volume: 14
    • Issue: 8
    • Pages: 2006
    • Citations: 10
  7. Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
    • Authors: A. Ottaiano, M. Berretta, C. Von Arx, M. Capozzi, M. Caraglia
    • Journal: Frontiers in Oncology
    • Year: 2022
    • Volume: 12
    • Pages: 852445
    • Citations: 1
  8. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
    • Authors: I.M. Modlin, M. Kidd, K. Oberg, I.A. Drozdov, A. Kitz
    • Journal: Annals of Surgical Oncology
    • Year: 2021
    • Volume: 28
    • Issue: 12
    • Pages: 7506–7517
    • Citations: 24
  9. Selinexor and the selective inhibition of nuclear export: A new perspective on the treatment of sarcomas and other solid and non-solid tumors
    • Authors: A.L. Marretta, G. Di Lorenzo, D. Ribera, A. Pizzolorusso, S. Tafuto
    • Journal: Pharmaceutics
    • Year: 2021
    • Volume: 13
    • Issue: 9
    • Pages: 1522
    • Citations: 2
  10. Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: A real-world experience from a cancer center
    • Authors: M. Piezzo, R. D’aniello, I. Avallone, M. De Laurentiis, P. Maiolino
    • Journal: Pharmaceutics
    • Year: 2021
    • Volume: 13
    • Issue: 5
    • Pages: 684
    • Citations: 3